Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2018

Open Access 01-12-2018 | Research

Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from Japan’s initiative on rare and undiagnosed diseases (IRUD)

Authors: Takeya Adachi, Noriaki Imanishi, Yasushi Ogawa, Yoshihiko Furusawa, Yoshihiko Izumida, Yoko Izumi, Makoto Suematsu

Published in: Orphanet Journal of Rare Diseases | Issue 1/2018

Login to get access

Abstract

Background

There is now an international partnership to establish global programs for patients with rare and undiagnosed diseases, involving interdisciplinary expert panels and phenotype-driven genetic analyses utilizing next-generation sequencing and analytics. Whereas it is crucial to have data such as the actual number of undiagnosed patients, to help inform the implementation plan with such programs, there have been no systematic studies to quantitate the numbers of patients principally because of the inherent difficulty in most health systems to identify patients whose condition has not yet been diagnosed and coded. Our national experience with a rare disease program, Nan-Byo which was established in 1972, and the more recently expanded Initiative on Rare and Undiagnosed Diseases (IRUD), provided a unique opportunity to design a cross-sectional study to ascertain the undiagnosed patients in Japan based on the IRUD referral criteria.

Results

Two rounds of online surveys were performed: one survey targeting physicians affiliated with general hospitals (GH) and family clinics (FC) (the response rate: 30.6% (242/792)) and one nationwide survey targeting university hospitals (UH) in Japan (47.1% (839/1781)). A high percentage of doctors needing IRUD was seen in pediatrics at GH, FC, while there was a clear demand for IRUD in most departments at UH. We calculated the number of undiagnosed patients in Japan, as the “percentage of doctors needing IRUD” × “number of patients who would be referred to IRUD per doctor needing IRUD (cases/person)” × “total number of doctors in the relevant facilities in Japan (persons)”, resulting in 3681 cases in pediatrics/pediatric surgery and 33,703 cases in other departments, for a total of 37,384 cases.

Conclusions

Our study revealed the extant demand for IRUD in most departments and 37,000+ potential patients with undiagnosed diseases in the Japanese health system. These data inform the establishment of an equitable, sustainable, efficient and effective outpatient-based IRUD. These findings would serve as a valuable reference for undiagnosed diseases programs in different international jurisdictions and for countries and regions who also share vision(s) for societal implementation that help to advance international efforts to support patients with rare diseases who are direly waiting for diagnosis, subsequent treatment and care.
Literature
1.
go back to reference Gahl WA, Tifft CJ. The NIH undiagnosed diseases program: lessons learned. JAMA. 2011;305:1904–5.CrossRef Gahl WA, Tifft CJ. The NIH undiagnosed diseases program: lessons learned. JAMA. 2011;305:1904–5.CrossRef
2.
go back to reference Taruscio D, Groft SC, Cederroth H, Melegh B, Lasko P, Kosaki K, et al. Undiagnosed diseases network international (UDNI): white paper for global actions to meet patient needs. Mol Genet Metab. 2015;116:223–5.CrossRef Taruscio D, Groft SC, Cederroth H, Melegh B, Lasko P, Kosaki K, et al. Undiagnosed diseases network international (UDNI): white paper for global actions to meet patient needs. Mol Genet Metab. 2015;116:223–5.CrossRef
3.
go back to reference Beaulieu CL, Majewski J, Schwartzentruber J, Samuels ME, Fernandez BA, Bernier FP, et al. FORGE Canada consortium: outcomes of a 2-year national rare-disease gene-discovery project. Am J Hum Genet. 2014;94:809–17.CrossRef Beaulieu CL, Majewski J, Schwartzentruber J, Samuels ME, Fernandez BA, Bernier FP, et al. FORGE Canada consortium: outcomes of a 2-year national rare-disease gene-discovery project. Am J Hum Genet. 2014;94:809–17.CrossRef
4.
go back to reference Firth HV, Wright CF, Study DDD. The deciphering developmental disorders (DDD) study. Dev Med Child Neurol. 2011;53:702–3.CrossRef Firth HV, Wright CF, Study DDD. The deciphering developmental disorders (DDD) study. Dev Med Child Neurol. 2011;53:702–3.CrossRef
5.
go back to reference Baynam G, Broley S, Bauskis A, Pachter N, McKenzie F, Townshend S, et al. Initiating an undiagnosed diseases program in the Western Australian public health system. Orphanet J Rare Dis. 2017;12:83.CrossRef Baynam G, Broley S, Bauskis A, Pachter N, McKenzie F, Townshend S, et al. Initiating an undiagnosed diseases program in the Western Australian public health system. Orphanet J Rare Dis. 2017;12:83.CrossRef
6.
go back to reference Adachi T, Kawamura K, Furusawa Y, Nishizaki Y, Imanishi N, Umehara S, et al. Japan’s initiative on rare and undiagnosed diseases (IRUD): towards an end to the diagnostic odyssey. Eur J Hum Genet. 2017;25:1025–8.CrossRef Adachi T, Kawamura K, Furusawa Y, Nishizaki Y, Imanishi N, Umehara S, et al. Japan’s initiative on rare and undiagnosed diseases (IRUD): towards an end to the diagnostic odyssey. Eur J Hum Genet. 2017;25:1025–8.CrossRef
7.
go back to reference Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, et al. Improved diagnosis and Care for Rare Diseases through implementation of precision public health framework: rare diseases epidemiology: update and review. Adv Exp Med Biol. 2017;1031:55–94.CrossRef Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, et al. Improved diagnosis and Care for Rare Diseases through implementation of precision public health framework: rare diseases epidemiology: update and review. Adv Exp Med Biol. 2017;1031:55–94.CrossRef
9.
go back to reference Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2015;378:1106–15.CrossRef Ikegami N, Yoo BK, Hashimoto H, Matsumoto M, Ogata H, Babazono A, et al. Japanese universal health coverage: evolution, achievements, and challenges. Lancet. 2015;378:1106–15.CrossRef
11.
go back to reference Wang K, Li P, Chen L, Kato K, Kobayashi M, Yamauchi K. Impact of the Japanese diagnosis procedure combination-based payment system in Japan. J Med Syst. 2010;34:95–100.CrossRef Wang K, Li P, Chen L, Kato K, Kobayashi M, Yamauchi K. Impact of the Japanese diagnosis procedure combination-based payment system in Japan. J Med Syst. 2010;34:95–100.CrossRef
12.
go back to reference Molster C, Urwin D, Di Pietro LD, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:30.CrossRef Molster C, Urwin D, Di Pietro LD, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:30.CrossRef
13.
go back to reference Nutt S, Limb L. Survey of patients’ and families’ experiences of rare diseases reinforces calls for a rare disease strategy. Soc Care Neurodisability. 2011;2:195–9.CrossRef Nutt S, Limb L. Survey of patients’ and families’ experiences of rare diseases reinforces calls for a rare disease strategy. Soc Care Neurodisability. 2011;2:195–9.CrossRef
14.
go back to reference Austin CP, Dawkins HJS. Medical research: next decade’s goals for rare diseases. Nature. 2017;548:158.CrossRef Austin CP, Dawkins HJS. Medical research: next decade’s goals for rare diseases. Nature. 2017;548:158.CrossRef
15.
go back to reference Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in rare disease research 2010-2016: an IRDiRC perspective. Clin Transl Sci. 2018;11:11–20.CrossRef Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in rare disease research 2010-2016: an IRDiRC perspective. Clin Transl Sci. 2018;11:11–20.CrossRef
16.
go back to reference Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, et al. Future of rare diseases research 2017-2027: an IRDiRC perspective. Clin Transl Sci. 2018;11:21–7.CrossRef Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D, et al. Future of rare diseases research 2017-2027: an IRDiRC perspective. Clin Transl Sci. 2018;11:21–7.CrossRef
22.
go back to reference Ramoni RB, Mulvihill JJ, Adams DR, Allard P, Ashley EA, Bernstein JA, et al. The undiagnosed diseases network: accelerating discovery about health and disease. Am J Hum Genet. 2017;100:185–92.CrossRef Ramoni RB, Mulvihill JJ, Adams DR, Allard P, Ashley EA, Bernstein JA, et al. The undiagnosed diseases network: accelerating discovery about health and disease. Am J Hum Genet. 2017;100:185–92.CrossRef
24.
go back to reference Lochmüller H, Torrent i, Farnell J, Le Cam Y, Jonker AH, Lau LPL, Baynam G, et al. The international rare diseases research consortium: policies and guidelines to maximize impact. Eur J Hum Genet. 2017;25:1293–302.CrossRef Lochmüller H, Torrent i, Farnell J, Le Cam Y, Jonker AH, Lau LPL, Baynam G, et al. The international rare diseases research consortium: policies and guidelines to maximize impact. Eur J Hum Genet. 2017;25:1293–302.CrossRef
Metadata
Title
Survey on patients with undiagnosed diseases in Japan: potential patient numbers benefiting from Japan’s initiative on rare and undiagnosed diseases (IRUD)
Authors
Takeya Adachi
Noriaki Imanishi
Yasushi Ogawa
Yoshihiko Furusawa
Yoshihiko Izumida
Yoko Izumi
Makoto Suematsu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2018
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-018-0943-y

Other articles of this Issue 1/2018

Orphanet Journal of Rare Diseases 1/2018 Go to the issue